EPISODE · Aug 14, 2020 · 21 MIN
Future Treatment Strategies for Acute Myeloid Leukemia—Emerging Targeted Therapy Combinations and Beyond
from Decera Clinical Education Oncology Podcast · host Decera Clinical Education
In this episode, Naval G. Daver, MD, discusses promising investigational agents and treatment combinations in clinical trials for patients with newly diagnosed and relapsed/refractory AML, including:FLT3 inhibitors crenolanib and quizartinibAnti-CD47 antibody magrolimabIMGN632, a CD123 antibody–drug conjugateAnti-CD70 antibody cusatuzumabAPR-246, targeting the TP53 mutationContent is part of an online CME program supported by an educational grant from Daiichi-Sankyo.Link to full program, including a ClinicalThought commentary: https://bit.ly/2Y2uCG2 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
What this episode covers
Listen to Naval G. Daver, MD, discuss his thoughts on the most promising investigational agents and treatment strategies currently in clinical trials for the treatment of patients with acute myeloid leukemia (AML).
NOW PLAYING
Future Treatment Strategies for Acute Myeloid Leukemia—Emerging Targeted Therapy Combinations and Beyond
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m